AstraZeneca PLC (AZN) annual results, year to 31 December 2024: revenue USD 54,073 million, from the 20-F
AstraZeneca PLC files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2024 it reported revenue of USD 54,073 million, up 18.0% on the year before. Its profit attributable to shareholders was USD 7,035 million, up 18.1%, and diluted earnings per share USD 4.50.
The year to 31 December 2024, against the year before
| Year to | Dec 2023 | Dec 2024 |
|---|---|---|
| Revenue | 45,811 | 54,073 |
| Cost of sales | 8,268 | 10,207 |
| Gross profit | 37,543 | 43,866 |
| Research and development | 10,935 | 13,583 |
| Selling, general and administrative | 19,216 | 19,977 |
| Operating profit | 8,193 | 10,003 |
| Finance costs | 1,626 | 1,742 |
| Profit before tax | 6,899 | 8,691 |
| Income tax | 938 | 1,650 |
| Profit for the year | 5,961 | 7,041 |
| Profit attributable to shareholders | 5,955 | 7,035 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2023 | Dec 2024 |
|---|---|---|
| Cash from operations | 10,345 | 11,861 |
| Purchase of property, plant and equipment | 1,361 | 1,924 |
| Free cash flow | 8,984 | 9,937 |
| Dividends paid | 4,481 | 4,629 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2023 | Dec 2024 |
|---|---|---|
| Total assets | 101,119 | 104,035 |
| Equity attributable to shareholders | 39,143 | 40,786 |
| Cash and cash equivalents | 5,840 | 5,488 |
| Borrowings, as filed | 28,622 | 30,295 |
| Lease liabilities | 1,128 | 1,452 |
| Trade and other receivables | 12,126 | 12,972 |
| Inventories | 5,424 | 5,288 |
| Goodwill | 20,048 | 21,025 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2023 | Dec 2024 |
|---|---|---|
| Gross margin | 82.0% | 81.1% |
| Operating margin | 17.9% | 18.5% |
| Net margin | 13.0% | 13.0% |
| Free cash flow margin | 19.6% | 18.4% |
| Return on year-end equity | 15.2% | 17.2% |
| Effective tax rate | 13.6% | 19.0% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024, this page
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021
- Year to 31 December 2020
- Year to 31 December 2019
- Year to 31 December 2018
- Year to 31 December 2017
- Year to 31 December 2016
- Year to 31 December 2015
Source
20-F for the year to 31 December 2024, filed 24 February 2026, accession 0001104659-26-019130: the filing on EDGAR. All of AstraZeneca PLC's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.